Gene marker for prognosis of pancreatic adenocarcinoma

Abstract

The invention relates to the field of clinical diagnosis of pancreatic adenocarcinoma, in particular to a gene marker for prognosis of pancreatic adenocarcinoma. The gene marker is an m5C regulatory gene. The invention further discloses application of the expression quantity of the m5C regulatory gene in prognosis of pancreatic adenocarcinoma. The gene marker for detecting pancreatic adenocarcinoma has the advantages of safety and noninvasiveness, and is high in detection acceptability even for asymptomatic population; RNA sources are wide, and a detection blind area in iconography does not exist; the gene marker is high in accuracy, has relatively high sensitivity and specificity to early pancreatic adenocarcinoma, and is suitable for early screening of pancreatic adenocarcinoma; and theoperation is convenient, and it is easy to dynamically monitor the recurrence and metastasis of pancreatic adenocarcinoma. The gene marker can be combined with other clinical indexes, so that more accurate judgment is provided for screening, diagnosis, treatment and prognosis of pancreatic adenocarcinoma.

Description

technical field [0001] The invention relates to the field of clinical diagnosis of pancreatic cancer, in particular to a gene marker for the prognosis diagnosis of pancreatic cancer. Background technique [0002] Pancreatic cancer is a common tumor of the digestive tract and one of the malignant tumors with the worst prognosis. According to the latest epidemiological survey, pancreatic cancer ranks fourth in the mortality rate of malignant tumors in developed countries such as Europe and the United States, and about 2.5 million people die of pancreatic cancer every year in the world. In the past 20 years, the incidence of pancreatic cancer in my country has continued to increase, and pancreatic cancer currently ranks fifth in the mortality rate of malignant tumors. [0003] Pancreatic adenocarcinoma (PAAD) is a highly malignant tumor of the digestive tract that is difficult to diagnose and treat. About 90% of pancreatic cancers are ductal adenocarcinomas originating from th...

AI Technical Summary

Problems solved by technology

[0004] In the treatment of pancreatic cancer, early diagnosis is difficult, its onset is hidden, it lacks typical clinical symptoms, and its prognosis is extremely poor. Pancreatic cancer is highly aggressive and malignant, and the curative effects of surgery, chemotherapy and radiotherapy are not satisfactory. , the 1-year survival rate after surgery is less than 20%, and the 5-year survival rate is only 4%. The low early diagnosis rate and postoperative metastasis are the main reasons for the high mortality rate of pancreatic cancer

Images